A biotech drug from Roche has become the first medicine approved to treat breast cancer before surgery, offering an earlier approach against one of the deadliest forms of the disease. The U.S. Food and Drug Administration (FDA) approved Perjeta for women with a form of early-stage breast cancer who face a high risk of having their cancer spread to other parts of the body.
A “vicious cycle” produces mucus that protects uterine and pancreatic cancer cells and promotes their proliferation, according to researchers at Rice Univ. The researchers offer hope for a therapeutic solution. They found that protein receptors on the surface of cancer cells go into overdrive to stimulate the production of MUC1, which covers the exposed tips of the elongated epithelial cells that coat internal organs to prevent infection.
Government cancer experts say a drug from Roche has shown effectiveness as a new option to treat breast cancer before tumor-removing surgery. The U.S. Food and Drug Administration panel voted 13-0, with one abstention, that the benefits of Perjeta as an initial treatment for breast cancer outweigh its risks.
A cross-disciplinary team of scientists, engineers and clinicians announced that they have begun a Phase 1 clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer. The effort is the fruit of a new model of translational research being pursued at Harvard Univ. that integrates the latest cancer research with bio-inspired technology development.
Federal regulators have approved Celgene Inc.'s drug Abraxane to treat late-stage pancreatic cancer. In experimental trials, the drug extended the lives of patients by a little less than two months more than those treated with the current standard drug.
Like naked mole-rats, blind mole-rats live underground in low-oxygen environments, are long-lived and resistant to cancer. A new study demonstrates just how cancer-resistant they are, and suggests that the adaptations that help these rodents survive in low-oxygen environments also play a role in their longevity and cancer resistance.
Two proteins have been identified as prime suspects in the proliferation of breast cancer in a study by an international consortium of researchers. The research may offer a path to therapies that could slow or stop tumors from developing. The research found that reducing the expression of a pair of proteins known as NEETs significantly reduced cancer cell proliferation and breast cancer tumor size.
A new study by Rice Univ. biophysicists offers the most comprehensive picture yet of the molecular-level action of melittin, the principal toxin in bee venom. The research could aid in the development of new drugs that use a similar mechanism as melittin’s to attack cancer and bacteria.
Researchers at the Univ. of Georgia are developing a new treatment technique that uses nanoparticles to reprogram immune cells so they are able to recognize and attack cancer. The human body operates under a constant state of martial law. Chief among the enforcers charged with maintaining order is the immune system. The immune system is good at its job, but it's not perfect.
A recent invention at Purdue Univ. could improve therapy selection for personalized cancer care. Researchers have created a technique called BioDynamic Imaging that measures the activity inside cancer biopsies, or samples of cells. It allows technicians to assess the efficacy of drug combinations, called regimens, on personal cancers.
Shares of Immunomedics jumped Wednesday after announcing that its treatment for a type of non-Hodgkin lymphoma helped to extend the lives of patients that used it in combination with another drug. The company said patients with newly diagnosed follicular lymphoma responded well to a combination of its epratuzumab and Roche's drug, Rituxan.
A hallmark of cancer is uncontrolled and sustained cell division. One particular overactive protein, STAT3, is implicated in this malfunction. Scientists have recently discovered a complex mechanism that regulates this protein’s activity in healthy cells.
For cancer patients, it’s not the primary tumor that is deadly, but the spread or “metastasis” of cancer cells from the primary tumor to secondary locations throughout the body that is the problem. That’s why a major focus of contemporary cancer research is how to stop or fight metastasis. Studies suggest that metastasizing cancer cells undergo a major molecular change when they leave the primary tumor—a process called EMT.
Some 60 years ago, a doctor in Baltimore removed cancer cells from a poor black patient named Henrietta Lacks without her knowledge or consent. Those cells eventually helped lead to a multitude of medical treatments and lay the groundwork for the multibillion-dollar biotech industry. Now, for the first time, the Lacks family has been given a say over at least some research involving her cells.
Stem cell therapy is in its infancy, but has the potential to change the way we treat cancer and other diseases by replacing damaged or diseased cells with healthy ones. Identifying the right cells to use is the challenge, and scientists in the U.K. have found a way to use gold nanoprobes with surface enhanced Raman spectroscopy to differentiate the nearly identical cells.
Reaching a clinic in time to receive an early diagnosis for cancer—when the disease is most treatable—is a global problem. And now a team of Chinese researchers proposes a global solution: have a user-friendly diagnostic device travel to the patient, anywhere in the world.
A research team at the National Institute for Materials Science in Japan has developed a new nanofiber mesh which is capable of simultaneously performing thermotherapy and chemotherapy of tumors. Using this new mesh, the team succeeded in efficiently inducing natural death of epithelial cancer cells.
Evidence is mounting that the development and spread of cancer, long attributed to gene expression and chemical signaling gone awry, involves a biomechanical component as well. Researchers at Lawrence Berkeley National Laboratory have added to this body of evidence by demonstrating that the malignant activity of a critical cellular protein system can arise from what essentially are protein traffic jams.
Scientists at the University of California, San Diego have designed tiny spherical particles to float easily through the bloodstream after injection, then assemble into a durable scaffold within diseased tissue. An enzyme produced by a specific type of tumor can trigger the transformation of the spheres into net-like structures that accumulate at the site of a cancer.
Scientists in Missouri have successfully created nanoparticles made of a radioactive form of the element lutetium. By covering these particles with gold shells and attaching targeting agents, they have a tool that can seek out dangerous secondary lymphoma tumors. They recently demonstrated the nanoparticles can find the tumors without attaching to or damaging healthy cells.
The University of Chicago has recently launched the first secure cloud-based computing system that enables researchers to access and analyze human genomic cancer information, such as the The Cancer Genome Atlas, without the costly and cumbersome infrastructure normally needed to download and store massive amounts of data.
Aerospace conglomerate United Technologies Corp. says it's donated $3 million to establish an endowed professorship at the Yale Cancer Center in New Haven. Lieping Chen will be the first United Technologies Corp. Professor in Cancer Research and is known for research leading to clinical trials of new cancer drugs that harness the body's immune system to fight cancer.
When cells suffer too much DNA damage, they are usually forced to undergo programmed cell death, or apoptosis. However, cancer cells often ignore these signals, flourishing even after chemotherapy drugs have ravaged their DNA. A new finding may offer a way to overcome that resistance: A team has identified a key protein involved in an alternative death pathway known as programmed necrosis.
Cancer patients could face high costs for medications under President Barack Obama's health care law, industry analysts and advocates warn. Where you live could make a huge difference in what you'll pay. To try to keep premiums low, some states are allowing insurers to charge patients a hefty share of the cost for expensive medications used to treat cancer, multiple sclerosis, rheumatoid arthritis, and other life-altering chronic diseases.
Eli Lilly and Co. said Friday it will stop development of an experimental cancer drug after it failed in a late-stage clinical trial. The company was studying enzastaurin as a treatment for diffuse large B-cell lymphoma, a cancer that affects a type of white blood cell. Lilly said patients who were treated with enzastaurin did not survive longer than patients treated with a placebo.